univers coverag
calendar event
medic meet medic informat world societi pediatr radiolog
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
trump-azar puls call drug price blueprint limit current hh
bottom line afternoon host medacorp puls call washington healthcar
polici specialist initi reaction us presid trump human servic hh
secretari azar american patient first blueprint blueprint drug price reform see initi
reaction friday trump-azar drug price propos conceptu practic
specialist note four challeng american drug market highlight blueprint
trump administr execut branch hh place highest prioriti address amount
senior pay drug medicar individu co-pay deduct
specialist believ current author hh would allow medicar part formulari
overhaul certain drug move part part suggest previously-fear measur
explicit price control direct contract tabl specialist also believ
fda commission scott gottlieb alreadi bought-in blueprint base
overlap initi alreadi advanc agenc mean new agenc guidanc speed
develop certain complex gener gener risk evalu mitig strategi
rem program could forthcom howev mani identifi blueprint challeng would
requir congression action take effect cost share breakdown medicar
broad pharmacy-level biosimilar substitut specialist believ impact measur
biopharma industri blueprint inflat cap part drug price increas also
includ presid budget final specialist suggest initi
rais price paid innov drug foreign govern consist presid polici
stanc likelihood signific progress close gap rais price intern
puls call recap continu action like remov overhang
bottom line recent host medacorp puls call polici specialist discuss presid
trump recent drug price speech blueprint publish hh call follow
prior note blueprint link overal specialist call agre view speech
blueprint continu trump administr broader push chang prescript drug
price multifacet approach take time hh document broke variou item
immedi futur action specialist call took differ view character
item achiev administr requir congression
legisl overal continu believ presid trump speech hh blueprint compris
next phase continu measur approach trump administr launch bid
chang system howev believ mani propos polici take time engin
implement believ pharmaci benefit manag pbm distributor abl
implement strategi process reduc much unfavor impact propos polici
legisl may need anyth involv money
chang part take time
increas competit seen administr greatest focu
posit pbm distributor
kol discuss mirvetuximab ahead multipl data readout
dcf analysi revenu multipl dr tgr
bottom line clinical-stag biotechnolog compani pioneer develop
antibodi drug conjug base therapi recal compani lead proprietari product candid
mirvetuximab soravtansin current phase develop forward-i single-ag
platinum-resist ovarian cancer addit on-going forward ii phase i/ii studi evalu
drug combin avastin keytruda carboplatin avastin advanced/metastat ovarian
cancer recent success complet interim analysi phase forward studi
mirvetuximab soravtansin platinum-resist ovarian cancer increment posit sever
import catalyst next month could provid good setup stock phase ii dose-
expans data forward-ii trial expect american societi clinic oncolog
annual meet avastin combin monday poster european societi
medic oncolog esmo cancer congress keytruda combin addit forward-i top-
line data expect ahead upcom data readout spoke two
medacorp kol highlight view opportun mirvetuximab soravtansin
ovarian cancer mirvetuximab soravtansin place treatment landscap describ within
updat american societi clinic oncolog includ
takeaway kol convers includ
valu micro-dystrophin program micro pt
bottom line sarepta one three compani develop micro-dystrophin gene therapi
duchenn muscular dystrophi dmd competit nr acquir
bamboo op solid clinic hold still place link
sarepta could potenti first-to-mkt expect report first clinic data
micro-dystrophin candid day june anticip potenti strong
clinic data micro-dystrophin gene therapi ad probability-weight
contribut micro-dystrophin gene therapi revenu model increas
valuat think logic consid current valuat
reiter op rate rais pt previous
expect preliminari updat day express would mark home run
beyond averag level express western blot uniform express proper protein
local immunohistochemistri interest sinc may provid insight eventu clinic
benefit potenti abil next-gener construct improv upon earlier gener one
neuromuscular specialist believ uniform express lower level better higher degre
express mosaic pattern
howev micro-dystrophin program still uncertainti
assum micro-dystrophin program contribut peak ww sale program risk-adjust
bottom line remain outperform agil given lead posit chemic energi
end-market maintain well-diversifi posit across healthcar growth market
pharma lst diagnost agil report deliv roughli in-lin result
organ revenu ep expect stock trade-off given higher expect
head quarter higher expect expens recent acquir lasergen
us agil becom top-lin growth stori long-term number new
product includ ultivo intuvo link gain share upsid like higher growth
lasergen launch aati drive accret near-term link reduc pt
expect higher expens lasergen acquisit drive lower earn reflect
impact china food agenc reorgan appear transitori sale return back agil
icp-m top-lin miss revenu made
dilut impact lasergen like stay investor mind agil post anoth solid quarter
agil host analyst day june new york citi
revenu us million ep exclud item amort intang
jame woy formerli hnt appoint evp health servic
bottom line announc appoint jame woy former hnt presid
central health servic mr woy lead employe across claim process
clinic servic qualiti risk adjust ancillari servic posit complement
recent appoint pam sedmak former ceo aet medicaid head health ls
appoint see moh ceo zubretski assembl season capabl team
achiev success margin oper turnaround op next catalyst wa
reprocur contract award may day may nyc
recap pipelin track safeti updat asco
blend discount sale multipl analysi dcf w/ discount rate termin growth rate
bottom line updat model reflect financi result also provid
pipelin updat in-lin expect mention continu dose
escal also announc new patent provid broad coverag flexim polymer-
base dolaflexin platform develop proprietari next-gener antibodi drug conjug
platform hold promis gener differenti properti compar
current avail agent clinic proof-of-concept still outstand space
competit multi-target partnership takeda merck kgaa valid mrsn approach
think assembl strong leadership team consist industri veteran gener
compel pipelin strategi view lead product candid take aim
larg market appear differenti roch kadcyla base preclin data
support on-going phase clinic trial phase data repres key de-risk event given
notori toler challeng mani adc face histor beyond
prolifer product engin expect drive organ pipelin growth longer term
second proprietari product candid current underway phase dose escal
studi ovarian cancer non-squam lung cancer tumor like express reiter
op pt
phase dose-escal studi on-going first interim clinic data
phase dose-escal studi on-going
expect suffici cash fund oper plan second half previous
least
revenu present mm gaap
may speech point bigger immedi action drug price
bottom line prepar remark morn hh secretari azar issu request
propos chang medicar part drug competit acquisit program asp
could shift incent current asp physician prescrib expens drug
secretari also highlight increas negoti remov protect statu six class
drug medicar part chang drug rebat fix price discount pbm medacorp
specialist state medicar commerci rebat pass accord
medacorp dc polici specialist chang medicar price model could done
cmmi center medicar medicaid innov demo allow waiv statut lieu
legisl rebat chang could done execut order secretari also reiter
propos merg medicar part part dc specialist note merg medicar part
could difficult implement especi non-or drug see mco integr
pbm part plan medicar advantag becom view import agent
chang op optum rx op today futur ci op esrx mp
op ingenio rx stronger buy thesi blueprint
blueprint thorough pbm like abl manag rebat
hr takeaway cabana unlik chang af practic dd growth
market transit valu base like acceler
 methodolog ep
recap pipelin track updat
gx proair delay lower ep ep impact could
may dova pdufa avathombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
may pdufa peg-pal pegvalias phenylketonuria pku
management remain optimist posit outcom fda convey
peg-pal pku shown lower blood phenylalanin amino acid accumul
pt phase studi
think neurocognit data requir fda registr base
discuss agenc
initi induction/titr phase like translat lower revenu per patient
management note meaning reduct phe consequ well ast
adult pt popul could lead attract market opportun almost sale
price releas upon approv management guid modest premium
ahead may pdufa management appear cautiou potenti launch
highlight lower dose use initi lower revenu per pt pegvalias
revenu may limit downsid impact revenu guidanc
yet pku clinic alreadi experienc pegvalias via clinic trial initi
physician pt feedback presum could help investor better project pku
june american societi clinic oncolog -- link titl note
earlier present interim clinic data phase ii studi margetuximab
plu mrk keytruda patient advanc line gastric cancer
expand studi enrol addit gastric cancer patient
compani present updat clinic biomark data year june
assign valu probability-weight sale margetuximab
gastroesophag cancer forecast sale
continu await product approv expect
delay believ ttoo long-term outlook depend approv
convers manag suggest fda approv near june time-fram
believ earli demand propos quarter indic
interest
given expect market clearanc expect ttoo add addit
sale rep order penetr hospit rep today ou
manag indic sale forc focus sell total solut rather
candida view appear fundament chang
remain unconvinc ttoo sale execut would like see
approv follow solid sale pickup soon
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therapi confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
continu optimist ahead pdufa given step taken scph
mitig potenti review risk
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
june akao pdufa plazomicin gram neg infect
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come base upon trajectori
agn avycaz accord medacorp kol gener major sale
off-label use infect
compani anticip report ph ii proof-of-concept data
management state observ reduct level -- marker glycem control
dose depend
compani anticip observ dose respons biomark reflect
drug mechan action
goal would posit agent line difficult-to-treat patient use
glycem control compani see potenti market appli
probabl success
model gross sale
believ investor expect head ph ii/iii data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
june present updat analysi pivot
cscc studi focus cemiplimab long-term activ durabl suggest
may addit data studi indic meet
sourc leerink research compani inform factset price prior day
fda adcom vaccin relat biolog product
hous rep commerc committe opioid legisl mark-up
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
fda adcom joint anesthet analges drug product drug safeti
fda ad\com anesthesiolog respiratori therapi devic
pdufa akao plazomicin complic urinari tract infect bloodstream
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
societi pediatr radiolog
abstract releas edt
societi investig dermatolog
american societi gene cell therapi bold
american associ clinic endocrinologist updat afirma
societi neurolog surgeon
world feder hemophilia link
ph phoenix bardoxolon data renal diseas adpkd lgan link note
european academi allergi clinic immunolog dbvt
american societi clinic psychopharmacolog
american colleg sport medicin
european feder nation associ orthopaed traumatolog
societi imag informat medicin
american societi clinic oncolog adap armo celg
american societi transplant surgeon
american societi neuroradiolog
american societi mass spectrometri
american societi microbiolog
associ profession infect control epidemiolog
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash highlight invokana fda warn puls call modest impact
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
biopharma -- flash highlight invokana fda warn puls call modest impact
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
achn recap increment advanc patent complement progress
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst outperform
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
moat vs
 insight april nyc hc servic day convict
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
